The role of biofilms: Are we hitting the right target?

Plastic and Reconstructive Surgery

Volumn 127, Issue SUPPL. 1 S, 2011, Pages

  Wolcott, Randall ^a   Dowd, Scot ^a  

^a Southwest Regional Wound Care Center Lubbock   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; BACTERIAL INFECTION; BIOFILM; CASE REPORT; CHEMICAL BURN; CHRONIC DISEASE; DIABETIC FOOT; GENETICS; HUMAN; MALE; PATHOPHYSIOLOGY; REVIEW;

ADULT; BACTERIAL INFECTIONS; BIOFILMS; BURNS, CHEMICAL; CHRONIC DISEASE; DIABETIC FOOT; HUMANS; MALE;

EID: 78651291684     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e3181fca244     Document Type: Article

References (58)

1. National Institutes of Health. Minutes of the National Advisory Dental and Craniofacial Research Council-153rd Meeting. 1997. Available at: www.nidcr.nih.gov/AboutNIDCR/Council AndCommittees/NADCRC/Minutes/Minutes53.htm. Accessed 2007.
2. del Pozo JL, Patel R. The challenge of treating biofilm-associated bacterial infections. Clin Pharmacol Ther. 2007;82:204-209.
3. Wolcott RD, Rhoads DD, Bennett ME, et al. Chronic wounds and the medical biofilm paradigm. J Wound Care 2010;19: 45-50, 52.
4. Kong K, Coates HL. Natural history, definitions, risk factors and burden of otitis media. Med J Aust. 2009;191(9 Suppl): S39-S43.
5. Foster TJ. Colonization and infection of the human host by staphylococci: Adhesion, survival and immune evasion. Vet Dermatol. 2009;20:456-470.
6. Veldkamp KE, van Strijp JA. Innate immune evasion by staphylococci. Adv Exp Med Biol. 2009;666:19-31.
7. Caldwell CC, Chen Y, Goetzmann HS, et al. Pseudomonas aeruginosa exotoxin pyocyanin causes cystic fibrosis airway pathogenesis. Am J Pathol. 2009;175:2473-2488.
8. Schalk IJ. Metal trafficking via siderophores in Gram-negative bacteria: Specificities and characteristics of the pyoverdine pathway. J Inorg Biochem. 2008;102:1159-1169.
9. Soberón-Chávez G, Lépine F, Déziel E. Production of rhamnolipids by Pseudomonas aeruginosa. Appl Microbiol Biotechnol. 2005;68:718-725.
10. Matsumoto K. Role of bacterial proteases in pseudomonal and serratial keratitis. Biol Chem. 2004;385:1007-1016.
11. Engel J, Balachandran P. Role of Pseudomonas aeruginosa type III effectors in disease. Curr Opin Microbiol. 2009;12:61-66.
12. Mutalik VK, Nonaka G, Ades SE, Rhodius VA, Gross CA. Promoter strength properties of the complete sigma E regulon of Escherichia coli and Salmonella enterica. J Bacteriol. 2009; 191:7279-7287.
13. Moscoso M, Garcia E. Transcriptional regulation of the capsular polysaccharide biosynthesis locus of streptococcus pneumoniae: A bioinformatic analysis. DNA Res. 2009;16: 177-186.
14. Brötz-Oesterhelt H, Beyer D, Kroll HP, et al. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat Med. 2005;11:1082-1087.
15. Melendez JH, Frankel YM, An AT, et al. Real-time PCR assays compared to culture-based approaches for identification of aerobic bacteria in chronic wounds. Clin Microbiol Infect. (in press).
16. Wolcott RD, Dowd SE. A rapid molecular method for characterising bacterial bioburden in chronic wounds. J Wound Care 2008;17:513-516.
17. Ehrlich GD. The need for PCR-based panel testing for syndromic infectious diseases. Mol Diagn. 1996;1:83-87.
18. Klouche M, Schroder U. Rapid methods for diagnosis of bloodstream infections. Clin Chem Lab Med. 2008;46:888-908.
19. Costerton JW. The Biofilm Primer. New York: Springer; 2007.
20. Fux CA, Costerton JW, Stewart PS, Stoodley P. Survival strategies of infectious biofilms. Trends Microbiol. 2005;13:34-40.
21. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: A common cause of persistent infections. Science 1999;284: 1318-1322.
22. Donlan RM, Costerton JW. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002; 15:167-193.
23. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: From the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2:95-108.
24. Stoodley P, Sauer K, Davies DG, Costerton JW. Biofilms as complex differentiated communities. Annu Rev Microbiol. 2002;56:187-209.
25. Leid JG, Willson CJ, Shirtliff ME, Hassett DJ, Parsek MR, Jeffers AK. The exopolysaccharide alginate protects Pseudomonas aeruginosa biofilm bacteria from IFN-gamma-mediated macrophage killing. J Immunol. 2005;175:7512-7518.
26. Balaban N, Stoodley P, Fux CA, Wilson S, Costerton JW, Dell'Acqua G. Prevention of staphylococcal biofilm-associated infections by the quorum sensing inhibitor RIP. Clin Orthop Relat Res. 2005;437:48-54.
27. Sauer K, Camper AK, Ehrlich GD, Costerton JW, Davies DG. Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm. J Bacteriol. 2002;184:1140-1154.
28. Wolcott RD, Rhoads DD, Dowd SE. Biofilms and chronic wound inflammation. J Wound Care 2008;17:333-341.
29. de Kievit TR. Quorum sensing in Pseudomonas aeruginosa biofilms. Environ Microbiol. 2009;11:279-288.
30. Gooderham WJ, Hancock RE. Regulation of virulence and antibiotic resistance by two-component regulatory systems in Pseudomonas aeruginosa. FEMS Microbiol Rev. 2009;33:279-294.
31. Hiller NL, Janto B, Hogg JS, et al. Comparative genomic analyses of seventeen Streptococcus pneumoniae strains: Insights into the pneumococcal supragenome. J Bacteriol. 2007;189: 8186-8195.
32. Buchinsky FJ, Forbes ML, Hayes JD, et al. Virulence phenotypes of low-passage clinical isolates of nontypeable Haemophilus influenzae assessed using the chinchilla laniger model of otitis media. BMC Microbiol. 2007;7:56.
33. Shen K, Sayeed S, Antalis P, et al. Extensive genomic plasticity in Pseudomonas aeruginosa revealed by identification and distribution studies of novel genes among clinical isolates. Infect Immun. 2006;74:5272-5283.
34. Ehrlich GD, Hu FZ, Shen K, Stoodley P, Post JC. Bacterial plurality as a general mechanism driving persistence in chronic infections. Clin Orthop Relat Res. 2005;437:20-24.
35. Smith EE, Buckley DG, Wu Z, et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA. 2006;103:8487-8492.
36. Nguyen D, Singh PK. Evolving stealth: Genetic adaptation of Pseudomonas aeruginosa during cystic fibrosis infections. Proc Natl Acad Sci USA. 2006;103:8305-8306.
37. Wolcott RD, Ehrlich GD. Biofilms and chronic infections. JAMA. 2008;299:2682-2684.
38. James G, Swogger E, Wolcott R, et al. Biofilms in chronic wounds. Wound Repair Regen. 2008;16:37-44.
39. Parsek MR, Singh PK. Bacterial biofilms: An emerging link to disease pathogenesis. Annu Rev Microbiol. 2003;57:677-701.
40. Ammons MC, Ward LS, Fisher ST, Wolcott RD, James GA. In vitro susceptibility of established biofilms composed of a clinical wound isolate of Pseudomonas aeruginosa treated with lactoferrin and xylitol. Int J Antimicrob Agents 2009;33:230-236.
41. Vande Berg JS, Rose MA, Haywood-Reid PL, Rudolph R, Payne WG, Robson MC. Cultured pressure ulcer fibroblasts show replicative senescence with elevated production of plasmin, plasminogen activator inhibitor-1, and transforming growth factor-beta1. Wound Repair Regen. 2005;13:76-83.
42. Charles CA, Romanelli P, Martinez ZB, Ma F, Roberts B, Kirsner RS. Tumor necrosis factor-alfa in nonhealing venous leg ulcers. J Am Acad Dermatol. 2009;60:951-955.
43. Rayment EA, Upton Z, Shooter GK. Increased matrix metalloproteinase- 9 (MMP-9) activity observed in chronic wound fluid is related to the clinical severity of the ulcer. Br J Dermatol. 2008;158:951-961.
44. Diegelmann RF. Excessive neutrophils characterize chronic pressure ulcers. Wound Repair Regen. 2003;11:490-495.
45. Dowd SE, Sun Y, Secor PR, et al. Survey of bacterial diversity in chronic wounds using pyrosequencing, DGGE, and full ribosome shotgun sequencing. BMC Microbiol. 2008;8:43.
46. Dowd SE, Wolcott RD, Sun Y, McKeehan T, Smith E, Rhoads D. Polymicrobial nature of chronic diabetic foot ulcer biofilm infections determined using bacterial tag encoded FLX amplicon pyrosequencing (bTEFAP). PLoS One 2008;3:e3326.
47. Leake JL, Dowd SE, Wolcott RD, Zischkau AM. Identification of yeast in chronic wounds using new pathogen-detection technologies. J Wound Care 2009;18:103-104, 106, 108.
48. Wolcott RD, Gontcharova V, Sun Y, Dowd SE. Evaluation of the bacterial diversity among and within individual venous leg ulcers using bacterial tag-encoded FLX and titanium amplicon pyrosequencing and metagenomic approaches. BMC Microbiol. 2009;9:226.
49. Basu S, Ramchuran PT, Bali ST, Gulati AK, Shukla VK. A prospective, descriptive study to identify the microbiological profile of chronic wounds in outpatients. Ostomy Wound Manage. 2009;55:14-20.
50. Moore K, Huddleston E, Stacey MC, Harding KG. Venous leg ulcers: The search for a prognostic indicator. Int Wound J. 2007;4:163-172.
51. Howell-Jones RS, Wilson MJ, Hill KE, Howard AJ, Price PE, Thomas DW. A review of the microbiology, antibiotic usage and resistance in chronic skin wounds. J Antimicrob Chemother. 2005;55:143-149.
52. Wolcott RD, Cox SB, Dowd SE. Healing and healing rates of chronic wounds in the age of molecular pathogen diagnostics. J Wound Care 2010;19:272-271.
53. Price LB, Liu CM, Melendez JH, et al. Community analysis of chronic wound bacteria using 16S rRNA gene-based pyrosequencing: Impact of diabetes and antibiotics on chronic wound microbiota. PLoS One 2009;4:e6462.
54. Rhoads DD, Wolcott RD, Percival SL. Biofilms in wounds: Management strategies. J Wound Care 2008;17:502-508.
55. Wolcott RD, Rhoads DD. A study of biofilm-based wound management in subjects with critical limb ischaemia. J Wound Care 2008;17:148-158, 150-152, 154-155.
56. Kiran MD, Giacometti A, Cirioni O, Balaban N. Suppression of biofilm related, device-associated infections by staphylococcal quorum sensing inhibitors. Int J Artif Organs 2008;31: 761-770.
57. Wolcott RD, Rumbaugh KP, James G, et al. Biofilm maturity studies indicate sharp debridement opens a time-dependent therapeutic window. J Wound Care 2010;19:320-328.
58. Balaban N, Cirioni O, Giacometti A, et al. Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP. Antimicrob Agents Chemother. 2007;51: 2226-2229.